Abstracts tagged "rheumatoid arthritis (RA) and psoriatic arthritis"

Abstract Number: 99 • 2019 ACR/ARP Annual Meeting
Mass Cytometry Immunophenotyping of Synovial Fluid from Checkpoint Inhibitor Related Arthritis
Runci Wang¹, Karmela Kim Chan ², Amy Cunningham-Bussel ³, Laura Donlin ⁴, Gregory Vitone ², Aidan Tirpack ², Caroline Benson ², Gregory Keras ³, Anna Helena Jonsson ⁵, Michael Brenner ⁶, Anne Bass ⁷ and Deepak Rao ¹, ¹Brigham and women's hospital, Boston, MA, ²Hospital For Special Surgery, New York, ³Brigham and women's hospital, Boston, ⁴Hospital For Special Surgery, New York, NY, ⁵Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁶Brigham and Women’s Hospital:, Boston, ⁷Hospital for Special Surgery/Weill Cornell Medicine, New York, NY
Background/Purpose: Anti-PD-1/PD-L1 checkpoint inhibitor therapies have produced remarkable results in stimulating immune responses against tumors. Checkpoint inhibitor therapy can also trigger a variety of autoimmune…
Abstract Number: 536 • 2019 ACR/ARP Annual Meeting
PERFUSE: A French Prospective/Retrospective Non-interventional Cohort Study of Infliximab-naïve and Transitioned Patients Receiving Infliximab Biosimilar SB2; An Interim Analysis
Bruno Fautrel¹, Yoram Bouhnik ², Guillaume Desjeux ³, Ulrich Freudensprung ⁴, Janet Addison ⁵ and Amira Brigui ⁶, ¹Pitié-Salpêtrière Hospital, Department of Rheumatology, AP-HP, Sorbonne University, UPMC university, Paris, Ile-de-France, France, ²Beaujon Hospital, Department of Gastroenterology, AP-HP, Paris Diderot University, Clichy, France, ³E-health Services Sanoïa, Digital CRO, Gémenos, France, ⁴Biogen International GmbH, Zug, Switzerland, ⁵Biogen UK, Maidenhead, United Kingdom, ⁶Biogen France SAS, Paris, France
Background/Purpose: SB2 is approved in the EU as an infliximab (IFX) biosimilar, having demonstrated bioequivalence and similar efficacy, safety and immunogenicity as the reference. There…
Abstract Number: 2095 • 2019 ACR/ARP Annual Meeting
A Quality Improvement Intervention to Improve Influenza and Pneumococcal Vaccination Rates in Immunosuppressed Inflammatory Arthritis Outpatients
Kieran Murray¹, Candice Low ¹, Francis Young ¹, Anna O'Rourke ¹, Ian Callanan ², Eoin Feeney ¹ and Douglas Veale ³, ¹Saint Vincent's University Hospital, Dublin, Ireland, ²Saint Vincent's University Hospital, Dublin, Dublin, Ireland, ³EULAR Centre For Arthritis And Rheumatic Diseases and The Conway Institute, Dublin, Ireland
Background/Purpose: The ACR and CDC recommend influenza (“flu”) and 23-valent pneumococcal polysaccharide (PPSV23) vaccination for inflammatory arthritis (IA) patients on immunosuppression. This study aimed to:…
Abstract Number: 2256 • 2019 ACR/ARP Annual Meeting
Patient Beliefs and Perceptions of Methotrexate for the Treatment of Rheumatoid Arthritis and Psoriatic Arthritis
W. Benjamin Nowell¹, Elaine Karis ², Kelly Gavigan ¹, Laura Stradford ¹, Scott Stryker ³, Shilpa Venkatachalam ¹, Gregory Kricorian ³ and Jeffrey Curtis ⁴, ¹Global Healthy Living Foundation, Upper Nyack, NY, ²Amgen Inc, Thousand Oaks, CA, ³Amgen Inc., Thousand Oaks, CA, ⁴University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Methotrexate (MTX) is a frequently used therapy in both Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA) due to its beneficial effects in both populations.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].